Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age
← catalyst calendarNCT07348692 · readout in 292 d
Sponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Prevention
Enrollment
2,195estimated
Sites
19
Countries
Honduras, Puerto Rico, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-01-20 | actual | When the study began enrolling |
| Primary completion | 2027-06-07 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-05-29 | estimated | The whole study's end, after follow-up |
| First posted | 2026-01-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Pneumococcal Immunization
- Healthy Volunteers
Interventions
- Biological: PCV21 vaccine — also filed as 515
- Biological: 20vPCV licensed vaccine — also filed as Prevnar 20™
Primary outcome
what the primary-completion date above is the date OFFor all participants: Serotype specific Immunoglobulin g (IgG) Geometric Mean Concentration (GMC)
measured 30 days after the third dose of PCV21 vaccine
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed